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Background: It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD patients on maintenance
treatment results in deterioration of symptoms, lung function and exacerbations. The aim of this real-life, prospective,
multicentric study was to investigate whether withdrawal of ICS in COPD patients at low risk of exacerbation is linked
to a deterioration in lung function and symptoms and to a higher frequency of exacerbations.
Methods: 914 COPD patients, on maintenance therapy with bronchodilators and ICS, FEV1>50% predicted, and <2
exacerbations/year were recruited. Upon decision of the primary physicians, 59% of patients continued their ICS
treatment whereas in 41% of patients ICS were withdrawn and regular therapy was continued with long-acting
bronchodilators mostly (91% of patients). FEV1, CAT (COPD Assessment Test), and occurrence of exacerbations were
measured at the beginning (T0) and at the end (T6) of the 6 months observational period.
Results: 816 patients (89.3%) concluded the study. FEV1, CAT and exacerbations history were similar in the two groups
(ICS and no ICS) at T0 and at T6. We did not observe any deterioration of lung function symptoms, and exacerbation
rate between the two groups at T0 and T6.
Conclusions: We conclude that the withdrawal of ICS, in COPD patients at low risk of exacerbation, can be safe
provided that patients are left on maintenance treatment with long-acting bronchodilators.
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Chronic Obstructive Pulmonary Disease (COPD) is a
major medical problem [1]. Regular therapy with long-
acting bronchodilators (LABA: long-acting beta-adrenergic
agonists; LAMA: long-acting antimuscarinic agents) im-
proves lung function, dyspnea and quality of life in symp-
tomatic patients with spirometric evidence of airflow
obstruction [2]. In addition, long-acting bronchodilators
can reduce the rate of exacerbations due probably to a
reduction in pulmonary hyperinflation and a re-setting of
lung function dynamics [3]. Additional treatment with in-
haled corticosteroids (ICS), in particular the ICS/LABA* Correspondence: andrea.rossi2@ospedaleuniverona.it
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unless otherwise stated.fixed dose combinations (FDC), has been recommended
for symptomatic COPD patients at a high risk of frequent
exacerbations, i.e. patients with severe airflow limitation
(FEV1 <50% predicted) and/or a clinical history of frequent
exacerbations (>2/year) [4]. However, several clinical stud-
ies have shown that COPD patients with moderate airflow
limitation, i.e. FEV1 > 50% predicted, and history of less
than 2 exacerbations per year, have also being treated with
ICS in clinical practice [5-7], although no recommendation
for this can be found in either international [2,4,8,9] or na-
tional [10] documents. This overtreatment is no trivial
matter [11]. In fact, it has been documented that regular
treatment with ICS for COPD patients can carry the risk of
significant adverse effects [12] particularly regarding an in-
creased risk of pneumonia [13-16]. A simple solutiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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it. However, it has been shown that withdrawing ICS in pa-
tients on maintenance treatment may increase the risk of
exacerbations, not only in comparison to placebo [17-19],
but also in comparison to regular treatment with long-
acting bronchodilators [20].
In fact, clinicians seem more confident in keeping pa-
tients on ICS rather than withdrawing it [21], even though
it can be regarded as a form of overtreatment [11] and
hence inappropriate according to guidelines. The COS-
MIC trial [20] recruited patients with severe airflow limi-
tation and frequent exacerbations. Hence, the effects of
withdrawal of ICS was not investigated in COPD patients
at low risk for exacerbations, such as those with moderate
airflow limitation, i.e. FEV1>50% predicted and no history
of frequent exacerbations, i.e. less than 2 per year. This
study was therefore undertaken to assess whether with-
drawal of ICS in these COPD patients is safe or whether it
is linked to a deterioration in lung function and symptoms
and to a higher frequency of exacerbations.Methods
Approval was obtained from the ethics committees of
each participating centre and written informed consent
forms were signed by all the patients.Study design
OPTIMO (Real-Life study On the aPpropriaTeness of
treatment In MOderate COPD patients) was a multicen-
ter, prospective, real-life study. Each pulmonary unit nom-
inated a pulmonologist to be in charge of the study, who
then attended a one-day start-up meeting before the ac-
tual study began to discuss the protocol, documents and
guidelines. Particular focus was directed on ACP-ACCP-
ATS-ERS [2], GOLD 2007 [8], GOLD 2011 [4], NICE [9]
as well as the Italian National Document on the Integrated
Management of COPD [22]. From July 2011 to April
2012, a total of 914 COPD patients were recruited in
accordance with the inclusion and exclusion criteria. This
was not to be a randomized clinical trial, but a prospect-
ive, real-life study and its design and flow chart are illus-
trated in Figure 1. Therefore, after having recruited the
patients at the T0 visit, their physicians were free to
prescribe whatever maintenance therapy they deemed fit.
This information was then sent to the central data analysis
office in AIPO (Associazione Italiana Pneumologi Ospeda-
lieri) based in Milan, Italy. An intermediate optional visit
three months on from enrollment could then be arranged,
according to the clinical practice of the centers. However,
the patients were encouraged to contact their pneumolo-
gical center for any particular need or query during the
study. A final visit was scheduled for all patients six
months on from enrollment (T6).Patients
Patients were recruited in 43 centers in Italy (pulmonary
units in both general and university hospitals), by their
own treating physicians, all of whom have had first-hand
experience of cooperating in real life studies [5]. Inclu-
sion criteria of entry to the study meant that patients
could be either gender, aged >40 years with an estab-
lished history of COPD and with spirometric evidence of
airflow obstruction. This meant a post-bronchodilator
FEV1/VC ratio <88% and <89% predicted for men and
women, respectively [23,24], and FEV1>50% predicted
having suffered less than 2 exacerbations in the year
prior to the study. The diagnosis of COPD was reported
in the patient’s case report form (CRF) by the caring
pulmonologist and based on patient’s clinical history and
spirometric evidence of post-bronchodilator airflow
obstruction. The latter was defined according to the
ERS-COPD document [23] and the ERS/ATS criteria
[24]. However, as expected on the basis of previous ana-
lysis [25] all our patients had a FEV1/VC ratio <0.70,
basically in line with the GOLD recommendation [4,8],
and very similar to the spirometric criteria in the COS-
MIC trial [20]. Patients were excluded if they had either
a clinical diagnosis or a history of asthma, if they were
on long-term oxygen therapy or if any COPD exacerba-
tion or respiratory infection had occurred in the month
before the recruitment visit (T0), if they had had serious
uncontrolled psychological disease, myocardial infarc-
tion, acute heart failure, or angina pectoris in the six
months preceding the visit. Patients with any kind of
history of alcohol or drug abuse were also excluded. All
of the above-listed characteristics had been ascertained
at the visit preceding recruitment. Patients who met all
the above criteria and who, according to their clinical
record, had been on regular treatment with ICS in the
previous year, were recruited at the T0 visit. At the same
time, their physicians filled in a pre-established CRF
entering all the information required for the study.
Measurements
Forced Expiratory Volume in one second (FEV1) was
calculated from the forced expiratory maneuver following
a slow Vital Capacity (VC) maneuver in accordance with
international protocol [24], and compared to ERS pre-
dicted values [26].
A COPD exacerbation was defined according to the
ECLIPSE study [27], i.e. a change in symptoms leading to
a brief course of antibiotics or systemic corticosteroids or
both, depending on what the treating physicians deemed
fit, and which was reported on the patient’s individual
record. As patients did not receive a diary card, which
would be the normal procedure in real life practice, mild
exacerbations, i.e. a change in medication decided by the
patients without consultation with her/his center, even
Figure 1 Study profile.
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erbations. However, it has to be noted that patients were
instructed and actively encouraged to contact their center
if they noticed their symptoms getting any worse. If the
patient needed to be hospitalized, either at the discretion
of the caring physician, or due to an emergency visit,
exacerbation was considered severe.
Symptoms were assessed by means of the CAT (COPD
Assessment Test, [28]) at the time of enrollment (T0)
and at the final visit after 6 months (T6).
Statistics
Results are expressed as mean and standard deviation if
variables are continuous, and as a percentage if variables
are categorical. Multiple regression model was used to
compare continuous variables (FEV1 and CAT) in the
different groups, adjusting for the confounders. Negative
binomial regression, for over-dispersed count data, wasused to compare the number of exacerbations in the
different groups, adjusting for the confounders.
A p-value <0.05 was to be considered statistically
significant. Analyses were performed using STATA
(StataCorp, College Station, TX, USA) version 12.0.
Results
Nine-hundred and fourteen COPD patients, on mainten-
ance therapy with LABA plus ICS in the preceding year,
from 43 pneumological centers in Italy were enrolled.
Five-hundred and ten patients (56%) were on treatment
with fluticasone/salmeterol 500/50 mcg bid, 165 patients
(18%) with budesonide/formoterol 400/12 mcg bid, 112
patients (12%) with beclometasone/formoterol 200/12mcg
bid, and 127 patients (14%) were taking ICS and LABA
from different inhalers. 341 patients (37%) did not report
any exacerbation in the year preceding T0, whereas 573
patients (63%) reported one exacerbation, in line with the
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(12%) had reported one hospitalization in the preceding
year, although this was not due to respiratory-related
causes in 25 of these. Therefore, 84 patients had one hos-
pital admission related to their respiratory condition. The
treating physicians decided to continue the treatment with
ICS in 546 patients (59.7%) whereas ICS were withdrawn
in 368 patients (40.3%).
Eight-hundred and sixteen patients (89.3%) concluded
the study 6 months later, as illustrated in Figure 1. 482/
816 patients (59%) continued their treatment with LABA/
ICS with the same maintenance regimen as in the previ-
ous year (ICS group), whereas in 334/816 (41%) patients
ICS were withdrawn and the treatment switched mainly
to long acting bronchodilators (no-ICS group). Table 1
shows the characteristics of the 914 patients who started
the study and the 816 patients who concluded the study,
for the two groups of no-ICS (change in treatment) and
ICS (no change in treatment) patients. The drop-out was
10.7% on the whole population, and 9.2% and 11.7% in the
“no-ICS” and “ICS” groups, respectively. In the ICS group
there is a higher prevalence of ex-smokers, and a slightly
greater VC% predicted. In the starting population, more
patients in the no-ICS group (32%) did not report comor-
bidities compared to the ICS group (24%). However, this
difference was not observed in the groups of patients who
concluded the study. Nevertheless, when we separated
the kind of comorbidities, as shown in Table 2, the
cardiovascular comorbidities (cardiac failure, ischemicTable 1 Characteristics of the population who were enrolled





Gender (%F) 30% 27%
Age (Yrs) 72.0 (9.5) 72.8 (9.1)
BMI 27.6 (5.1) 28.3 (5.1)
Smoking history° (%Y) 82% 91%
Ex-smokers 60% 69%
Smokers 22% 22%
Years since diagnosis 6.8 (6.7) 6.6 (6.0)
VC (%pred) 91.5 (15.9) 95.2 (19.5)
FEV1 (%pred) 71.7 (10.4) 70.8 (11.3)
FEV1/VC 0.60 (0.08) 0.59 (0.08)
CAT 15.9 (8.5) 14.8 (7.8)
Exacerbations (0/1) 135/233 206/340
Comorbidities: 0 116 (32%) 130 (24%)
Comorbidities: 1 110 (30%) 174 (32%)
Comorbidities: ≥2 142 (38%) 242 (44%)
Data are presented as N, unless otherwise stated. Values are expressed as mean (SD
BMI: Body Mass Index; VC: Vital Capacity; FEV1: Forced Expiratory Volume in 1 secon
°Y = includes currents smokers and ex-smokers.hearth disorders, systemic arterial hypertension) were more
present in the ICS group compared to the no-ICS group.
No other difference was observed. In particular, the two
groups were comparable at baseline for the variables ana-
lyzed in the study, namely CAT, FEV1, and exacerbations.
CAT and FEV1 did not change from T0 to T6 in either
group and no difference was found between the groups at
T6 (Figure 2A and B). During the six months of the study,
229/816 patients (28%) reported at least one exacerbation.
In this group, 185 patients reported one exacerbation
while 44 patients reported >1 exacerbation: 35 patients, 6
patients, and 3 patients reported 2 exacerbations, 3 exac-
erbations, and 4 exacerbations, respectively. Therefore,
the total number of exacerbations in the six months of the
study amounted to 285 exacerbations. 141/482 patients
(29%) and 88/334 patients (26%) exacerbated in the group
treated with ICS and without ICS, respectively (Figure 3).
In all, 173 exacerbations were reported in the ICS group
and 112 in the non-ICS group, i.e. 0.37 and 0.34 exacerba-
tion/patient/6 months. As illustrated in Figure 4, there is
no significant difference (p = 0.321). Since the exacerba-
tion rate distribution had a high variability (standard devi-
ation greater than the mean), we analyzed the data with
negative binomial regression model for over dispersed
count data. The RR of the two groups (ICS vs NO ICS) is
not significantly different (p = 0.321) after adjusting for
confounding factors (age, smoke habits, FEV1 %pred (T0),
BMI and gender) as illustrate in Table 3. The goodness of
the model, compared to the Poisson regression model, isat baseline and who concluded the study






0.4102 30% 27% 0.2817
0.1750 72.1 (9.2) 73.0 (8.9) 0.1936
0.0600 27.8 (5.1) 28.4 (5.1) 0.1458
0.0007 83% 91% 0.0019
0.0047 60% 68% 0.0187
1.0000 23% 23% 1.0000
0.5401 6.8 (6.6) 6.6 (6.0) 0.6794
0.0054 91.4 (15.7) 94.7 (18.6) 0.0124
0.2608 71.6 (10.5) 71.1 (11.4) 0.5293
0.2679 0.60 (0.08) 0.59 (0.08) 0.1865
0.0717 16.0 (8.6) 14.8 (7.8) 0.0528
0.802 127/207 186/296 0.928
0.012 102 (30%) 109 (23%) 0.285
0.575 101 (30%) 153 (32%) 0.800
0.088 131 (40%) 220 (45%) 0.390
).
d; CAT: COPD Assessment Test.
Table 2 Comorbidities in the two groups who concluded






Cardiovascular 52% 64% 0.001
Obesity 17% 19% 0.523
Gastric reflux 13% 14% 0.918
Diabetes 13% 12% 0.787
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cantly different from zero.
Forty-two patients, who did not exacerbate in the pre-
vious year reported ≥1 exacerbations in the 6 months of
observation: 18/334 (5%) and 24/482 (5.3%) in the no-
ICS and ICS group respectively. On the other hand, 34%
and 39% of patients in the ICS and no-ICS group
respectively, went from 1 to 0 exacerbations. No signifi-
cant difference. Twenty-seven patients were hospitalized,
twenty of which due to respiratory-related causes: 15
patients in the ICS group (3.1% of 482), and 5 in the no-
ICS group (1.5% of 334).
As shown in Figure 1, among the 334 patients in whom
the initial LABA/ICS treatment was changed, monother-
apy with tiotropium 18mcg/die or LABA was instituted
for 89 patients (27%) and 147 patients (44%), respectively.
In this latter group, 98 (29%) patients received indacaterol
150mcg/die, and 49 patients (15%) were treated with
either formoterol 12mcg/bid or salmeterol 50mcg/bid. In
67 patients (20%) the association of tiotropium 18mcg
with indacaterol 150mcg was prescribed for regular treat-
ment. In 31 patients (9%) the treating physicians pre-
scribed either short-acting bronchodilators, in general
salbutamol, and/or theophylline. Therefore, in the major-
ity of patients, the therapy was “downgraded” from the
LABA-ICS combination to a bronchodilator monother-
apy. In a minority of patients the therapy was switched to
the association of two long acting bronchodilators. Table 4
shows the baseline characteristics of the patients in the
different groups of changed treatment. The distribution of
patients with exacerbations at T0 among the different
groups of treatment, after ICS withdrawal is also shown in
Table 4. The prevalence of exacerbations was 66% and
54% in the “downgraded” (monotherapy) and in the
tiotropium + indacaterol groups, respectively. After the
6 months of observation, the prevalence of exacerbations
at T6 was as follows: tiotropium 27/89 (30%), LABA 32/
147 (21%), indacaterol 22/98 (22%), and other 13/31
(42%), with a total of 35% (94/267) in the “downgraded”
group compared to a 24% (16/67) in the tiotropium +
indacaterol group. The number of patients in each group
is small and too different in magnitude for any additional
statistical comparison, which however was not in the
scope of this study. Furthermore, the data in Table 4 referto one year preceding the study, while the data at the end
of the study refer to 6 months only. It is noticeable that
the patients switched to the tiotropium plus indacaterol
combination had, on average, the higher CAT and lower
FEV1 %predicted compared to the other groups. Figure 5
(A and B) shows the data of mean FEV1 and CAT at T0
and T6 for the groups. No significant difference.
In the year preceding the enrollment, 17 patients re-
ported an episode of pneumonia. During the six months
of observation, 3 new cases of pneumonia were reported:
two in the group without ICS and one in the group con-
tinuing ICS treatment. We did not observe any death in
the six months of the study.
Discussion
This real-life, prospective study shows that withdrawal of
ICS in symptomatic COPD patients with moderate airflow
limitation, i.e. FEV1>50% predicted, and no history of fre-
quent exacerbations, i.e. having suffered less than 2 exac-
erbations in the year prior to the study, was not associated
with any deterioration in symptoms, lung function, and
exacerbation rate during six months of observation. The
data were analyzed having adjusted for all the confound-
ing variables at baseline. Although a minority (9%) of pa-
tients were switched to short-acting bronchodilators and/
or theophylline, the substantial majority of the patients
(91%) were switched to long-acting bronchodilators, either
in monotherapy (71%) or in association (20%). To the best
of our knowledge, this is the first study to show that with-
drawal of ICS in COPD patients for whom ICS are not
recommended by international documents and guidelines
can be safe provided that the patients remain on regular
treatment, for the most part with long-acting bronchodila-
tors. The results of this real-life study support the recom-
mendation of international documents [4] and guidelines
[9] that regular treatment with ICS is not needed in
COPD patients who are at low risk of exacerbations.
It is interesting to note that, though the mean FEV1 was
greater than 50% predicted in all patients in this study, the
average CAT value was greater than 10 points. In other
words, the COPD patients in this study had moderate-to-
mild airflow obstruction, but they did report symptoms.
They could be classified as patients B in the new GOLD
categories [4]. However, this is of no great surprise as the
elegant work by Ofir and colleagues [29] showed that
COPD patients with mild airflow obstruction, GOLD
stage 1 [8], had a lower exercise tolerance than control
subjects and that they interrupted their exercise mostly
for breathlessness, whereas control subjects stopped
mainly for leg fatigue.
Exactly what benefits COPD patients can hope for from
regular treatment with ICS remains controversial [21] and
a discussion on this issue goes well beyond the scope of
this study which aimed to investigate the consequence of
Figure 2 Mean (SE) of FEV1 % predicted (A) and of CAT score (B) at T6 in the two groups of patients who were switched to long acting
bronchodilators or continued their treatment with ICS.
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ledge that the lack of randomization is a major limitation
of this study and that we cannot draw a definitiveconclusion which requires a randomized controlled trial.
However, Table 1 shows that the only differences between
the two groups of patients who concluded the study are
Figure 3 Percentage of patients without exacerbations at the end of the study (T6).
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VC% predicted, although it was in the normal range, in the
no-ICS population. However, Table 3 shows that smoking
habits did not have any significant effect on the occurrence
of exacerbations. Furthermore, although the prevalence of
patients with comorbidities did not differ between the two
groups of patients who concluded the study, the presence
of cardiovascular comorbidities was greater in the ICS
group. It is possible that the presence of cardiovascular
comorbidities could have influenced the decision of the
caring pulmonologists at T0 not to discontinue the ICS
treatment. However, for all the other variables such as age,Figure 4 Mean (SE) exacerbation rate expressed as exacerbation/pati
patients who were switched to long acting bronchodilators (NO ICS)gender, BMI, years since diagnosis, and in particular for the
variables specifically examined in this study, namely CAT,
FEV1, and exacerbations, there was no significant differ-
ence either at the beginning or at the end of the study
between the no-ICS and ICS groups of patients. Further-
more, the population of COPD patients enrolled in this
study is rather numerous compared to the other, random-
ized, trials on the same topic [17-20].
It is of note that, in this real-life study, some interesting
information comes from the fact that the treating pulmo-
nologists were free to choose the maintenance treatment
for their patients. In fact, the majority decided to continueent/6 months at the end of the study (T6) in the two groups of
OR continued the treatment with ICS.
Table 3 Negative binomial regression model for over
dispersed count data (numbers of exacerbations)
Exacerbations (T6) RR (95% CI) Std. err. p-value
ICS* 0.8777 (0.679-1.135) 0.115 0.321
Age 1.004 (0.999-1.018) 0.007 0.594
Smoke habits 0.834 (0.576-1.207) 0.157 0.335
FEV1%pred (T0) 1.008 (0.997-1.020) 0.006 0.170
CAT (T0) 1.035 (1.020-1.052) 0.008 0.000
BMI 0.980 (0.956-1.005) 0.013 0.122
Gender 1.043 (0.786-1.385) 0.151 0.768
Constant 0.174 (0.343-0.881) 0.144 0.058
Alpha** 0.239 (0.065-0.878) 0.159 0.043
(pseudo R2 = 0.0199; p-value = 0.0012).
*reference group “NO ICS”.
**parameter for over dispersed count data (likelihood-ratio test of alpha = 0).
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on the explicit recommendations from international [2,4,
8,9] and national [10,22] documents. It cannot be said
therefore that doctors, and even specialists, fail to follow
the guidelines due to a lack of available information. There
are other explanations which need to be investigated [21].
It seems not to be a problem specific to a single country
such as Italy: in the multi-centric and multi-country
ECLIPSE [27] and UPLIFT studies [30], about 60% of
patients in GOLD stage 2 were treated with ICS.
The effect of discontinuing ICS in patients with COPD
was investigated in a few studies [31]. In the COPE study





Gender (%F) 28% 25%
Age (Yrs) 72.0 (9.6) 71.5 (8.1)
BMI 27.4 (4.8) 27.2 (4.8)
Smoking history° (%Y) 79% 78%
Years since diagnosis 5.4 (6.6) 8.7 (8.6)
VC (%pred) 96.1 (16.7) 90.5 (15.9)
FEV1 (%pred) 75.2 (15.6) 72.0 (8.2)
FEV1/VC 0.61 (0.10) 0.60 (0.08)
CAT 13.8 (7.2) 13.3 (5.8)
Exacerbations (0/1) 35/54 13/36
Comorbidities: 0 31 (35%) 20 (41%)
Comorbidities: 1 23 (26%) 16 (33%)
Comorbidities: ≥2 35 (39%) 13 (26%)
Data are presented as N, unless otherwise stated. Values are expressed as mean (SD
BMI: Body Mass Index; VC: Vital Capacity; FEV1: Forced Expiratory Volume in 1 secon
°Y = includes current smokers and ex-smokers.therapy with fluticasone 500 mcg/bid were randomized ei-
ther to continue fluticasone (123 patients) or to receive
placebo (121 patients) for 6 months. In the placebo arm
there was a higher recurrence-risk of exacerbations and a
significant deterioration in health-related quality of life.
The WISP study [19] was conducted in the primary care
setting. 260 COPD patients were taken off their usual ICS
therapy and were administered 500mcg fluticasone bid
(128 patients) or placebo (132 patients) for one year. The
risk of exacerbation increased in patients withdrawn from
ICS and was associated with a deterioration in symptoms.
Similar results were found in a smaller 6-week study: ven-
tilatory function and dyspnea worsened in severe COPD
patients when ICS were withdrawn [17]. However, those
studies compared ICS to a placebo arm.
In the COSMIC study, Wouters and colleagues [20]
enrolled almost 500 COPD patients after three months of
treatment with the fluticasone/salmeterol 500/50mcg
bid combination and monitored them for 1 year after
randomization to a continuation arm (189 patients) or to
a salmeterol 50mcg bid monotherapy arm (184 patients).
They found that the switch from the fluticasone/salme-
terol combination to salmeterol alone resulted in persist-
ent deterioration of lung function and dyspnea and in an
increase in mild exacerbations, while there was no signifi-
cant difference for moderate-to-severe exacerbations. To
our knowledge, the COSMIC is the only study in which
patients remained on regular treatment with a long-acting
bronchodilator after withdrawal of ICS. However, the pa-
tients in the COSMIC study had 2 or more exacerbationsoups of treatments (NO ICS)








71.4 (10.0) 73.4 (9.7) 71.7 (9.4)
27.5 (4.9) 28.3 (5.6) 28.0 (5.3)
84% 86% 83%
7.3 (5.8) 6.4 (6.3) 7.2 (7.0)
91.2 (14.8) 88.6 (14.9) 89.4 (17.0)
72.8 (10.2) 67.5 (6.9) 68.1 (12.1)
0.60 (0.08) 0.59 (0.08) 0.59 (0.04)
14.7 (8.0) 21.9 (9.2) 15.0 (8.6)
33/65 31/36 10/21
32 (33%) 17 (26%) 6 (19%)
27 (27%) 24 (36%) 10 (31%)
39 (40%) 26 (38%) 15 (50%)
).
d; CAT: COPD Assessment Test.
Figure 5 Mean (SE) of FEV1 % predicted (A) and of CAT score (B) at T0 and T6 in the different groups of treatments (NO ICS).
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predicted at both enrollment and randomization. By con-
trast, the patients in our study had a FEV1 >50% predicted,
the FEV1 amounting on average to 71.2% predicted in the
whole population, and less than 2 exacerbations in the
preceding year was a criterion for enrollment. Therefore,
whereas the patients in the COSMIC study met the basic
criteria for the ICS/LABA combination treatment, thepatients in our study can be defined as “low risk” patients
for exacerbations according to the classic (GOLD II) [8] as
well as to the most recent GOLD classification (GOLD B)
[4]. In addition to the difference in patient populations, i.e.
“high risk” in the COSMIC versus “low risk” in this study,
there was also a difference in protocol design. Our study
is a prospective, real-life survey in the secondary care
environment, not a randomized trial. Furthermore, the
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lasted 6 months. However, the deterioration in lung func-
tion and symptoms in the salmeterol monotherapy group
in the COSMIC was already clear well before 6 months.
In this regard, it should be noted that the COPE was also a
6-months study [18]. Therefore, we believe that the results
of our study, which showed no deterioration in the no-ICS
group, may be considered valid. In addition it has to be
considered that the recruiting period, in our study, went
from July 2011 to April 2012, hence including both a sum-
mer and a winter season. In the COSMIC study, no differ-
ence was observed between arms for the moderate-to-
severe exacerbations, whereas an increase was reported in
the rate of mild exacerbations [20]. Therefore the result on
moderate and severe exacerbations is similar in the two
studies. We did not examined specifically the issue of mild
exacerbations. The patients did not have a diary card. How-
ever, all the changes in symptoms that patients reported to
their caring pulmonologists at the referring center were re-
corded. No such increase was observed in our study.
Whether some patients had the “unreported exacerbations”
remains unknown in this as well as in many other studies.
Unlike the COSMIC trial, clinicians in our study were
free to choose which regular treatment to prescribe to
their patients after withdrawing ICS. In the vast majority
of cases, doctors prescribed regular treatment with long
acting bronchodilators (91%) either in mono-therapy or in
combination. Therefore, in the majority of patients, the
change was a downgrade to a long acting bronchodilator
mono therapy (236/334, 71%) whereas in 67 patients
(20%) the LABA/ICS combination was switched to a
tiotropium + indacaterol association. Table 4 shows that
the patients in the latter group had, on average, a lower
FEV1 % predicted, a higher CAT score, but not a greater
occurrence of exacerbations. The analysis of these data
goes beyond the possibility of the present study. In fact,
we addressed the issue of ICS withdrawal not the subse-
quent therapeutic choice. However, the data on Table 4
might suggest that doctors upgrade the bronchodilating
therapy in patients with a worse FEV1 and more symp-
toms. A recent study has shown that the combination of
indacaterol and tiotropium provides greater therapeutic
benefits than tiotropium alone [32].
In the ILLUMINATE study [33] the once-daily QVA149
(indacaterol 110 μg and glycopyrronium 50 μg) was com-
pared with salmeterol-fluticasone 50/500 μg bid fixed dose
combination. For the QVA149 arm, the ICS had been
withdrawn. No deterioration of symptoms, lung function,
and exacerbations was observed in comparison with the
ICS arm. The patients of the ILLUMINATE study were at
low risk as the patients of our study. We believe that those
data from ILLUMINATE support our conclusion.
In our study, hospital admissions were numerically more
frequent in the ICS than in the non-ICS group: 15 (3.1%)vs 5 (1.8%). This might be due to the greater prevalence of
cardiovascular comorbidities in the ICS group (Table 2).
Only a few cases of pneumonia were reported during the
six months of observation. However, it is known that
pneumonia may represent a risk for prolonged treatment
with ICS in COPD patients [13-16].
Conclusions
This real-life, prospective study suggests that the
withdrawal of ICS in patients at low risk of exacerba-
tion, namely patients with moderate airflow limitation
(FEV1 >50% predicted) and having suffered less than
two exacerbations in the year preceding the study, can
be safe provided that patients are left on maintenance
treatment with long-acting bronchodilators. Although
this is not a randomized controlled trial, the data support
this conclusion and can stimulate a controlled clinical trial
on this important issue in respiratory medicine.
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